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Introduction
Over the decades, improvements have been made in acute graft-versus-host disease (aGvHD) prevention. 
In contrast, chronic GvHD (cGvHD), which is often preceded by aGvHD, continues to be a significant 
cause of  morbidity and mortality, affecting an estimated 50% of  allogeneic hematopoietic stem cell 
Chronic graft-versus-host disease (cGvHD) remains a major complication of allogeneic stem cell 
transplantation requiring novel therapies. CD146 and CCR5 are expressed by activated T cells 
and associated with increased T cell migration capacity and Th17 polarization. We performed 
a multiparametric flow cytometry analysis in a cohort of 40 HSCT patients together with a 
cGvHD murine model to understand the role of CD146-expressing subsets. We observed an 
increased frequency of CD146+ CD4 T cells in the 20 patients with active cGvHD with enhanced 
RORγt expression. This Th17-prone subset was enriched for cells coexpressing CD146 and CCR5 
that harbor mixed Th1/Th17 features and were more frequent in cGvHD patients. Utilizing a 
murine cGvHD model with bronchiolitis obliterans (BO), we observed that donor T cells from 
CD146-deficient mice versus those from WT mice caused significantly reduced pulmonary 
cGvHD. Reduced cGvHD was not the result of failed germinal center B cell or T follicular helper 
cell generation. Instead, CD146-deficient T cells had significantly lower pulmonary macrophage 
infiltration and T cell CCR5, IL-17, and IFN-γ coexpression, suggesting defective pulmonary 
end-organ effector mechanisms. We, thus, evaluated the effect of TMP778, a small-molecule 
RORγt activity inhibitor. TMP778 markedly alleviated cGvHD in murine models similarly to agents 
targeting the Th17 pathway, such as STAT3 inhibitor or IL-17–blocking antibody. Our data suggest 
CD146-expressing T cells as a cGvHD biomarker and suggest that targeting the Th17 pathway may 
represent a promising therapy for cGvHD.
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transplantation (HSCT) patients (1, 2). Efforts have been made to characterize proteomic and cellular 
biomarkers to better define disease severity, predict therapeutic responses, and improve our understand-
ing of  cGvHD pathogenesis (3–7).
Donor T effector cells (Teffs) have been shown to mediate alloreactivity toward recipient tissue in both 
human and mice (2, 8, 9) and are required elements of  aGvHD and cGvHD generation. Both in vitro 
or in vivo T cell depletion have reduced but not eliminated cGvHD incidence, and both can be associat-
ed with increased infections and malignancy recurrence as complications. Offsetting GvHD-causing Teffs 
are regulatory mechanisms that serve to dampen the immune destructive responses that can harm the 
organism. These include cell-surface molecules such as coinhibitory receptors; metabolic control switches 
such as the indoleamine 2,3-dioxygenase tryptophan catabolic pathway; and cellular mechanisms such as 
Tregs. Relevant to cGvHD in patients, we previously showed that patients developing cGvHD presented 
altered Treg homeostasis with quantitative deficiency (5). Strategies to expand Tregs in vivo were efficient 
at reducing but not uniformly eliminating disease severity (10). Similarly, we observed abnormal homeosta-
sis and chronically activated B cells (6, 11), offering the possibility to deplete or target them (12–14). Thus, 
approaches to be used in combination with Treg augmentation would be desirable. Identifying a new Teff  
cell involved in the pathogenesis of  the disease would be a key step forward to develop prophylactic, thera-
peutic, and prognostic means of  reducing the consequences of  cGvHD in patients.
GvHD-causing Teffs can be contained within Th cell subsets that have been progressively defined 
according to the expression of  surface markers, activation molecules, and chemokine receptors and their 
capacity to secrete cytokines. Nomenclature defining Th polarization (Th1, Th2, Th9, Th17, Th22, etc.) is 
expanding with the further complexity that Th cells maintain a degree of  plasticity, being able to convert 
from one subset to another (15). The Th17 subset is defined according to the expression of  RAR-orphan 
receptor γ transcription factor (RORγt) (16) and the capacity to secrete IL-17 upon stimulation. In addi-
tion, different surface markers have been described, such as chemokine receptor 6 (CCR6), CD161, CCR4, 
IL-23R, and CD5L to characterize the Th17 subset (17, 18). Several studies have attempted to decipher 
the role of  Th17 in aGvHD (19, 20). However, murine models presented conflicting results, as IL-17–KO 
donor T cells either reduced (21) or exacerbated aGvHD (22). Similarly, human aGvHD studies reported 
discordant results. Indeed, blood/tissue Th17 cells were found to be either increased (23) or decreased (24, 
25). Interestingly, some studies provided data suggesting Th17 involvement in the transition from aGvHD 
to cGvHD. Indeed, Chen et al. reported the expansion of  Th17 in the early phase of  aGvHD playing a role 
in the development of  later autoimmune-like disease (26) and, in parallel, Carlson et al. described the role 
of  Th17 in severe skin and lung injuries that resemble cGvHD (27).
With respect to the pathogenesis of  cGvHD, the role of  Th17 cells is less controversial. Studies have 
demonstrated a role for Th17 cells in murine models with features of  autoimmunity (26), scleroderma (28), 
and multiorgan system disease with bronchiolitis obliterans (BO) in a CSF-1/CSF-1R– (29) and STAT3-de-
pendent manner (30, 31). In humans, there is a paucity of  data. Dander et al. showed an increase of  Th17 
cells in the blood of  patients with active cGvHD (23), and a mixed Th1/Th17 signature was observed in 
the skin of  patients with active disease (32). More recently, we identified candidate biomarkers (CCL14 and 
CD146) in the plasma of  patients developing gastrointestinal (GI) GvHD that revealed an activated Th17-
prone T cell population (CD4+CD146+CCR5+ T cells) participating in the pathogenesis of  aGvHD (33). 
Interestingly, CD146 appeared associated with cGvHD in our recent large-scale proteomic study (7). Alto-
gether, these data suggest studying the role of  Th17cells and the RORγt pathway during cGvHD pathogen-
esis, and targeting this subset may provide a clinical benefit.
Strategies specifically targeting the Th17 subset have included antibody-mediated neutralization of  
IL-17 or IL-23 and were predominantly evaluated in the field of  autoimmune diseases (34–36). The Th17 
program is dependent on the master regulator RORγt and STAT3 signaling. Dual RORγt or STAT3 path-
way inhibitors have been developed, such as the small GTPase, ρ-associated coiled-coil containing protein 
kinase 2 (Rock2) inhibitor, KD025. We recently showed that KD025 was efficient in suppressing murine 
and human cGvHD through inhibition of  RORγt and STAT3, leading to reduced IL-17 and IL-21 cytokine 
production and T follicular helper (TFH) cells that can support pathogenic antibody production during 
cGvHD (31, 37). Via its effects on STAT5, Treg production also is facilitated (31, 38). Other inhibitors can 
provide a more specific approach by targeting the Th17 program (e.g., RORγt), only without affecting all 
downstream STAT3 signaling (e.g., TFH and Th17), in order to preserve other immune functions such as 
humoral immunity (STAT3/4-dependent) (39, 40). One such small-molecule RORγt inhibitor is TMP778, 
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which acts through several modalities: interruption of  RORγt binding its target genes, disrupting RORγt 
interaction with other transcription factors or coactivators, and promotion of  Gata3 transactivation (40). 
Previous reports demonstrated the role of  TMP778 interfering with Th17 cell differentiation and its activity 
during mouse models of  autoimmune diseases (40, 41). Molecular studies showing a STAT3-dependent 
mechanism of  action suggest RORγt inhibitor use as a candidate treatment of  cGvHD.
Here, we show that CD146-expressing cells are increased in the context of  cGvHD in both human and 
mice, and they harbor a Th17 polarization with upregulation of  RORγt and increased capacity to secrete 
IL-17. This population was required for cGvHD pathogenesis, as CD146 KO, anti–IL-17 neutralizing anti-
body, and RORγt-specific inhibition (TMP778) each alleviated disease severity. Altogether, our data sup-
port that RORγt inhibitors could be used as a new therapeutic option for cGvHD.
Results
Increased frequencies of  CD146+ and CD146+CCR5+ CD4 T cell subsets during cGvHD. CD146 and CCR5 repre-
sent 2 molecules facilitating migration of  T cells through the endothelium in response to homing signals 
released from inflamed tissues (42, 43). We previously demonstrated that patients with GI GvHD presented 
an increased frequency of  CD146+CCR5+ T cells compared with patients without GvHD or nonenteritis 
GvHD, or with isolated skin GvHD (33). These observations suggest a role for the involvement of  this 
population in late aGvHD manifestations. To evaluate the role of  CD146- and CCR5-expressing cells in 
the pathogenesis of  human cGvHD, we performed multiparameter flow cytometry on peripheral blood 
samples from 40 HSCT patients with and without active cGvHD (n = 20 patients/group) at the time of  
sample collection. Patient clinical characteristics are listed in Table 1.
First, we analyzed the expression of  CD146 within CD4 conventional T cells (Tcon), defined as non-
Tregs (i.e., excluding CD25hiCD127low cells). CD146 was significantly upregulated in CD4 Tcon during 
cGvHD compared with patients without cGvHD (median percentage: 6.76 during active cGvHD vs. 3.28 
without cGvHD, P < 1 × 10–4) (Figure 1, A and B). Interestingly, CD146+ Tcon appeared to be positively asso-
ciated with cGvHD disease severity, according to NIH criteria (Figure 1B). We also analyzed the subset coex-
pressing CD146 and CCR5 (CD146+CCR5+). Although representing a smaller fraction within CD4+ T cells, 
CD146+CCR5+ within the Tcon subset was significantly increased during active cGvHD (median percentage: 
0.62 during active cGvHD vs. 0.27 without cGvHD, P = 0.015) (Figure 1C), similar to the CD146+ fraction. 
We also examined CD4+ Treg (defined as CD25hiFoxP3+) and found, similarly to aGvHD (33), a significant 
upregulation of  CD146 (median percentage: 21.65 during active cGvHD vs. 13.2 without cGvHD, P = 1 × 
10–4) (Figure 1D) and an increased frequency of  the double-positive subset (CD146+CCR5+) within the Treg 
subset (median percentage: 3.4 during active cGvHD vs. 2.1 without cGvHD, P = 0.007) (Figure 1E) during 
cGvHD. We observed similar findings when looking at absolute counts (Supplemental Figure 1, A–D; sup-
plemental material available online with this article; https://doi.org/10.1172/jci.insight.92111DS1). As we 
previously showed the increase of  CD146-expressing subsets in a cohort of  aGvHD, we analyzed our active 
cGvHD cohort, in which half  had previously developed aGvHD. This analysis did not reveal any impact 
of  prior aGvHD development (Supplemental Figure 1, E–J). Taken together, these data indicate that both 
CD146+ and CD146+CCR5+ T cell subsets with increased migration capacity are increased during cGvHD.
CD146-expressing CD4+ T cells are skewed toward a Th17 profile during cGvHD. We next evaluated whether 
CD146+ Tcons that were increased in patients with cGvHD expressed a specific polarization profile. Previ-
ous reports suggested that CD146+ subsets tended to be polarized toward a Th17 phenotype and function 
(44). As RORγt is a major transcription factor contributing to the Th17 polarization of  a T cell subset, 
we assessed its expression level by flow cytometric quantification of  mean fluorescent intensity (MFI) in 
healthy donor (HD) samples (Supplemental Figure 2, A–C) and confirmed the upregulation of  RORγt in 
CD146+ CD4 (Supplemental Figure 2A) and CCR5+ CD4 (Supplemental Figure 2, B and C) Tcon, as well 
as Treg subsets, in addition to the CD146+CCR5+ CD4 Tcon subset (Supplemental Figure 2, B and C). We 
then evaluated the relative RORγt expression levels among HSCT patients with or without active cGvHD. 
In our cohort, RORγt expression was increased in active cGvHD patients compared with no cGvHD when 
examining effector CD4+ T cells (CD4+ Tcon, median RORγt MFI: 244 vs. 197, respectively, P = 0.0045) 
(Figure 2, A and B), as well as in both the CD146+ CD4 Tcon (median MFI: 291.5 vs. 244.5, respectively, 
P = 0.029) (Figure 2C) and CD146+CCR5+ CD4 Tcon (median MFI: 356 vs. 269.5, respectively, P = 0.042) 
subsets (Figure 2D). The same trends were observed for the CD4+ Treg (median RORγt MFI: 192 vs. 156.5 
for active cGvHD and no cGvHD, respectively, P = 0.0066) (Figure 2E), as well as in CD146+ CD4 Treg 
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(median MFI: 200 vs. 160.5, respectively, P = 0.0056) (Figure 2F), and CD146+CCR5+ CD4 Treg (medi-
an MFI: 210.5 vs. 162, respectively, P = 0.0007) (Figure 2G) subsets. Since RORγt upregulation in Tregs 
may have affected Treg function, we assessed suppressor function according to CD146 expression levels 
in an in vitro suppression assay with Tcon. We observed a significantly decreased suppressive capacity of  
CD146+ Treg compared with CD146– Treg (Figure 2H). Taken together, these data suggest that CD146- 
and CD146/CCR5-expressing cells, in both Tcon and Treg, are polarized toward a Th17 phenotype, which 
is augmented during cGvHD and may contribute to its pathogenesis.
CD146+CCR5+ CD4 T cell subsets harbor a mixed polarization. Because the chemokine receptor CCR5 is 
associated with Th1 polarization (45), we also evaluated T-bet expression, a canonical transcription fac-
tor of  Th1 subset, within our population of  interest. In HDs, CCR5 expression within Tcon had a greater 
impact on T-bet upregulation compared with CD146 (T-bet mean MFI: 661.5 in CD146–CCR5+ vs. 446.3 
in CD146–CCR5–, P = 0.0078; 661.5 in CD146–CCR5+ vs. 520.9 in CD146+CCR5–, P = 0.07) (Supple-
mental Figure 2, D–F). We then evaluated IFN-γ production as a key Th1 signature cytokine. Consistent 
with T-bet upregulation data, the CD146–CCR5+-expressing subset produced a greater amount of  IFN-γ 
compared with the reciprocal CD146+CCR5– subset (mean IFN-γ production: 66.15 vs. 23.69, respective-
ly, P = 0.002) (Supplemental Figure 3, A–C). Together, our data showed in HD that CD146+CCR5+-ex-
pressing CD4+ T cells present both features of  Th1 (T-bet/IFN-γ) and Th17 (RORγt/IL-17), with CD146 
driving most of  the Th17 phenotype (Supplemental Figure 2, B and C, and Supplemental Figure 3, 
D–F). As CD146+ and CD146+CCR5+ CD4 T cells are highly correlated (Spearman’s r = 0.81, P = 0.016, 
in HD), we evaluated whether CD146+-expressing CD4+ T cells were enriched for a Th1/Th17 subset 
previously described as pathogenic. When we analyzed CD146+ CD4 T cells, we observed a significant 
enrichment of  a population secreting both cytokines IFN-γ+IL-17+ (mean percentage: 2.36% for CD146+ 
subset vs. 0.179% for CD146–, P = 0.002; and 4.579% for CD146+CCR5+ vs. 0.236% for CD4+ exclud-
ing the CD146+CCR5+ subset, P = 0.002) (Supplemental Figure 3, G–I). Interestingly, in our cohort, 
the Th1/Th17 (IFN-γ+IL-17+) subset within CD146+ CD4 T cells appeared to be associated with active 
cGvHD disease severity (Supplemental Figure 4) (median percentage of  IFN-γ+IL-17+CD146+ in CD4+ 
T cells: 0.0152% for mild vs. 0.0438% for moderate, P = 0.064; 0.0438% for moderate vs. 0.075% for 
severe, P = 0.367; P = 0.048 between mild and severe).
Table 1. Clinical characteristics of HSCT patients
Active cGvHD
n = 20
No cGvHD
n = 20
Age Median (range) 59
(25.9–75.6)
60.4
(32.6–74.9)
Sex ratio M/F 1.85 1
Conditioning regimen MAC 6 9
RIC 14 11
Graft Source BM 1 5
PBSC 19 15
Donor MRD 6 8
MUD 11 10
mmUD 3 2
Time from SCT (months) Median (range) 31.4
(11.5–123.8)
37.7
(12–140.9)
aGvHD (%) Grade 2–4 10 (50) 3 (15)
cGvHD NIH grade (%) Mild 8 (40) N/A
Moderate 8 (40) N/A
Severe 4 (20) N/A
IST at the time of sample Yes (%) 14 (70) 1 (5)
Steroid at the time of sample Yes (%) 8 (40) 0
Mean steroid dose mg/kg/day 0.18 N/A
M, male; F, female; MAC, myeloablative conditioning; RIC, reduced intensity conditioning; MRD, matched related donor; 
MUD, matched unrelated donor; mmUD, mismatched unrelated donor; PBSC, peripheral bood stem cell; SCT, stem cell 
transplantation; aGvHD, acute GvHD; cGvHD, chronic GvHD; IST, immunosuppressive therapy.
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Figure 1. CD146 and CCR5 expression within CD4+ Tcon (non CD25hiCD127low within CD4+ T cells) and Treg (CD25hiFoxP3+ 
within CD4+ T cells) subsets. (A) Color plots representing the gating strategy of CD146-expressing cells according to 
CD45RA, and representative examples of CD146+ and CD146+CCR5+ subsets (in CD4+ T live lymphocyte gate) in 1 active 
cGvHD patient and 1 patient without cGvHD. (B–E) Data shown are dot plots (mean ± SEM) according to different clini-
cal groups: No (n = 20) or active cGvHD (n = 20) and different clinical grades of cGvHD according to NIH criteria (mild, n = 
8; moderate, n = 8; severe, n = 4). Unpaired t test comparing the frequencies between groups. Comparisons in B–E were 
analyzed using the Wilcoxon rank-sum test.
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CD146 deficiency of  donor T cells alleviates mouse cGvHD model that includes BO. Here, our data from human 
samples suggest a role for the CD146+ subset in the pathogenesis of  cGvHD. Thus, we hypothesized that 
HSCT with CD146-KO donor T cells would preclude cGvHD generation using a well-established multiorgan 
cGvHD mouse model system that has BO as a prominent clinicopathological manifestation. We previously 
showed that B10.BR (H2k)recipients receiving BM and splenocytes from C57BL/6 (B6) donors developed a 
systemic multiorgan system cGvHD with BO mimicking human cGvHD (shown by pulmonary functional 
tests and lung fibrosis), representing a powerful tool to evaluate therapeutic interventions to better under-
stand cGvHD pathogenesis and assess pharmacological interventions (12, 31, 46, 47). In this model, donor 
T cells mediate cGvHD via a RORγt-, STAT3-, and IL-17/IL-21–dependent mechanism (28, 31). In addi-
tion, pulmonary fibrosis was shown to depend upon Th17 (48) and donor macrophages in the context of  
cGvHD-related BO (29). When using splenocytes from CD146-KO vs. WT donors (together with WT BM), 
pulmonary functional tests (resistance, compliance, elastance) performed 2 months after transplant were each 
significantly improved and comparable with BM-only mice that did not develop cGvHD (Figure 3A). There 
was a statistical trend toward decreased lung histopathology (Figure 3B), while histopathology in other tar-
get organs (liver and colon) was not decreased (data not shown) in the CD146-KO group as compared with 
the WT group. Similarly, organ fibrosis assessed by trichrome staining of  lung cryosections demonstrated 
markedly decreased collagen deposition with CD146-KO donors compared with WT (Figure 3C) and was 
quantitatively confirmed using a hydroxyproline assay to measure collagen burden (Figure 3D), whereas, con-
sistent with histopathological analysis, no significant differences were seen in liver and colon fibrosis (data not 
shown). Flow cytometry of  single-cell suspensions was performed to quantify the frequency of  pathogenic T 
Figure 2. Analysis of Th17-related transcription factor according to CD146 and CCR5 expression. (A) Single parameter histogram representing RORγt 
expression and comparing the level of expression in naive CD4+ T cells (CD45RA+) with the 1 in CD146+ CD4 T cells in 1 active-cGvHD and 1 no-cGvHD 
representative patients. (B–G) RORγt intracellular staining in CD146+ and CD146+CCR5+ subsets (Tcon and Treg) revealed a skewed polarization toward a 
Th17 profile in cGvHD patients. Data shown are dot plots (mean ± SEM) according to different clinical groups: No (n = 18) or active cGvHD (n = 18). Unpaired 
t test comparing RORγt MFI between groups. (H) Comparison of Treg suppressive capacity according to CD146 expression. Treg were sorted according to 
the expression of CD146 and cocultured with CFSE-labeled Tcon for 5 days at different ratios upon stimulation with coated αCD3 and soluble αCD28. Bar 
graph representing mean ± SEM values after 6 experiments. *P < 0.05, paired t test. Comparisons in B–G were analyzed using the Wilcoxon rank-sum test. 
Comparisons in H were analyzed using the Wilcoxon signed-rank test.
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cell subsets with Th17-related features within the lung. Similar to patient data, mice developing cGvHD had 
a significant increase in the IFN-γ+IL-17+ subset within both CD146+ and CD146+CCR5+ fractions, which 
was abrogated when using splenocytes from CD146-KO donors (Figure 4A). As we previously showed the 
involvement of  macrophages in the lung fibrosis (29), we undertook the quantification of  CD68 expression on 
lung cryosection and observed a marked increase in macrophage number during cGvHD that was alleviated 
in mice receiving CD146-KO splenocytes (Figure 4B). We also previously showed that development of  BO 
during murine cGvHD was associated with increased T foll cells along with germinal center B cells (GC B 
cells) within the spleen (47). Splenic flow cytometry indicated no difference in TFH or GC B cells between the 
mice receiving CD146-KO vs. WT T cells (Figure 4C). Taken together, our data indicate that CD146 expres-
sion on donor T cells is necessary for cGvHD BO development and infiltration of  pathogenic IFN-γ+IL-17+ 
subset and macrophages in the lung, rather than via direct effects on splenic TFH/GC B cell interactions.
Figure 3. CD146-expressing T cells are necessary for the development of cGvHD and lung fibrosis in a bronchiolitis obliterans 
model. B10.BR mice were transplanted with WT B6 BM without or with WT B6 T cells or B6 CD146–KO T cells as mentioned. (A) 
Mice were evaluated at day 60 for pulmonary function, measurement at day 56 after HCT, n = 8 per group. (B) Histopathology 
score of the lung at day 56 after HCT, n = 3 per group. (C) Lung sections were stained with trichrome for collagen deposition, 20× 
magnification. Representative data from 3 experiments. (D) Hydroxyproline quantitative measure in the lung of euthanized 
mice, n = 3–6 mice per group. Comparisons in A, B, and D were analyzed using the Wilcoxon rank-sum test.
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Figure 4. CD146 deficiency of donor T cells is associated with decreased pathogenic IFN-γ+IL-17+ T cells and macrophage infiltration, but an intact 
TFH–GC B cell axis. (A) Flow cytometry was performed on single-cell suspension from lungs of different animal groups analyzed by flow cytometry 
at day 56, after stimulation with PMA-ionomycin in the presence of protein transport inhibitor. Data represent frequencies (mean ± SEM) of IFN-
γ+IL-17+ subset within CD146+ (left panel) or CD146+CCR5+ fractions (right panel). (B) Lung cryosection were stained for CD68 expression (macro-
phages) together with DAPI to quantify cellular infiltrate. A representative example of immunofluorescence staining is shown of animals receiving 
BM only, BM + WT splenocytes (cGvHD), or BM + CD146-KO splenocytes (20× magnification). Automated quantification of macrophages relative to 
cellular infiltrate was performed to ensure reproducible analysis and is summarized in terms of frequencies (mean ± SEM). n = 3 mice per group, BM 
only n = 2. (C) CD146-KO does not impact T-B cross talk within lymphoid organ. GC B cells (CD19+GL7+Fashi) and TFH (CD4+CXCR5+PD1hiFoxP3–) were 
analyzed by flow cytometry after spleen digestion at day 56 after transplant in animals receiving BM only, BM + WT splenocytes, or BM + CD146-KO 
splenocytes. n =3–7 mice per group. Comparisons in A–C were analyzed using the Wilcoxon rank-sum test
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We and others have previously described the role of  CD146 and ICOS stimulation in the development 
of  human pathogenic IFN-γ+IL-17+ T cells (33, 49). Therefore, we sought to confirm the role of  both 
CD146 and ICOS in murine IFN-γ+IL-17+ T cells by differentiating naive CD146-KO vs. CD146 WT T 
cells with either CD3/CD28 stimulation or CD3/ICOS stimulation. We showed that Th17 differentiation 
conditioning and ICOS stimulation significantly increased the number of  cells coexpressing IL-17/IFN-γ 
and RORγt/IL-21 in cultures derived from naive CD146 WT T cells as compared with cultures derived 
from naive CD146-KO T cells (Supplemental Figure 5). These data suggest a crucial role of  CD146 in the 
development of  IFN-γ+IL-17+ T cells and BO model that point to an effect on the Th17-related homing 
capacity of  pulmonary macrophages, similar to the Th17-dependent BO observed in lung transplant (48).
TMP778 targeting of  RORγt suppresses the development of  pathogenic Th1/Th17 and CD146+CCR5+ CD4 T 
cells in vitro. We have now shown that CD146+CCR5+ CD4 T cells are Th17 committed, express higher 
levels of  Th17 markers, and exhibit a pathogenic Th1/Th17 phenotype (coexpressing IL-17 and IFN-γ) 
(15). Toward clinical translation, we sought to determine whether potentially pathogenic Th1/Th17 cell 
differentiation could be blocked in vitro. Therefore, we measured the effect of  TMP778, an inhibitor of  the 
Th17 master transcription factor RORγt, on in vitro human Th1/Th17-polarized cells and CD146+CCR5+ 
CD4 T cells. Total CD4 T cells from HD were cultured under Th17 polarizing condition in the presence 
of  increasing doses of  TMP778 or vehicle control DMSO. TMP778 significantly reduced the frequency of  
IFN-γ+IL-17+ T cells in a dose-dependent manner (Figure 5A). In addition, the frequency of  CD146+C-
CR5+ T cells was also inhibited in a dose-dependent manner (Figure 5B). Similarly, TMP778 at a concen-
tration of  0.1 μM and 1 μM significantly inhibited the generation of  Th1/Th17 and CD146+CCR5+ CD4 
T cells in allogeneic mixed lymphocyte reaction (MLR) cultures (Supplemental Figure 6). Together, our 
results indicate that TMP778 can suppress not only the differentiation of  Th17, but also the development 
of  Th1/Th17 and CD146+CCR5+ CD4 T cells in vitro.
Pharmacological and neutralizing antibody inhibition of  RORγt, STAT3, or IL-17 reverses established mouse 
cGvHD. Results above suggested a relationship between CD146 and Th17 polarity. Thus, we evaluated the 
in vivo cGvHD effect of  pharmacological inhibition of  RORγt with a small-molecule inhibitor that showed 
strong efficiency in other Th17-driven disease (40) and under the in vitro Th17 polarizing conditions from 
HD described immediately above. TMP778 interacts with RORγt to hamper its transcription factor activity 
and, consequently, IL-17 secretion (40, 41). Toward clinical translation, we treated recipients with TMP778 
beginning on day 28 (d28) at the time of  established cGvHD. TMP778 treated mice showed a significant 
improvement of  pulmonary function tests at d60, reaching the level of  recipients receiving CD146-KO sple-
nocytes or BM only (Figure 6). Similarly, administration of  an anti–IL-17 blocking antibody on d28 signifi-
cantly improved each of  the pulmonary function test parameters, alleviating BO-related cGvHD (Figure 6).
Discussion
In the present study, we sought to identify and characterize a new T cell subset involved in human and 
murine cGvHD. Defining cellular biomarkers of  cGvHD, such as T cell subsets, remains a major goal in 
order to improve our understanding and to develop targeted therapies. Here, we define a pathogenic CD4 T 
cell population based on the expression of  CD146 and CCR5 reflecting its capacity to migrate to inflamed 
tissue and to interact with endothelial barriers in the context of  alloreactivity.
CD146 (also called melanoma cell adhesion molecule [MCAM]) is a cell adhesion glycoprotein 
expressed on lymphoid cells, endothelial cells, smooth muscle cells, and tumor cells, and displays 
homophilic or heterophilic interaction (50). It has been shown to play a major role in T cell migra-
tion through interaction with endothelial cells (33, 43). Hence, CD146 expression on T cells has been 
shown as a surrogate of  subsets with transendothelial migration capacity (33) during the course of  
inflammation. Our study revealed that patients with active cGvHD had significantly higher CD146 
expression in CD4 T cells, including both Tcon and Treg subsets.
CD146 can be upregulated on T cells upon TCR or mitogen stimulation, reflecting T cell activation. 
When binding CD146 through homophilic interaction, downstream transducing signals induce phosphory-
lation of  cellular proteins such as Pyk2, focal adhesion kinase, and paxillin, thus promoting transendothelial 
migration (43). Similarly, we also evaluated another subset of  CD146-expressing cells, the CD146/CCR5 
double-positive CD4 T cells, which were increased in patients with cGvHD. These CD146-expressing CD4 T 
cells (including CD146+CCR5+) exhibited Th17 features. Specifically, CD146+CD4 T cells express a signifi-
cantly higher concentration of  RORγt and IL-17 intracellular expression upon stimulation. Previous reports 
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showed that CD146-expressing T cells upregulated IL-17, IL-22, and CCR6 mRNA (44). Here, we observed 
in patients with active cGvHD an increased expression of  RORγt within CD146+ or CD146+CCR5+ T cells 
(Tcon and Treg), suggesting a strong Th17 signature during cGvHD. The role of  CD146 in Th17 differenti-
ation remains poorly understood; however, we previously showed using shRNA (CD146) experiments that 
naive CD4 T cells cultured under Th17 polarizing conditions had reduced capacity to produce IL-17 and 
IFN-γ (33). We have now confirmed these data using murine naive CD146-KO T cells. Thus, CD146 expres-
sion appears as a surrogate marker for IL-17 and IFN-γ pathogenic subset without precluding for a mecha-
nistic role. Interestingly, CD146-expressing Treg showed a decreased suppressive capacity consistent with the 
upregulation of  RORγt. This underlines the altered homeostasis between Treg and Tcon previously described 
(5), along with the potential impact of  a defective function within regulatory subsets during cGvHD.
CCR5 is a chemokine receptor for CCL14 and CCL5, secreted at inflammatory sites, shown to promote 
the homing of inflammatory Teff subset, such as Th1 (45). We showed that CCR5-expressing CD4 T cells 
expressed greater levels of T-bet and IFN-γ. CCR5-expressing CD4 T cells have been evaluated in the context of  
aGvHD, but no reports investigated its implication on circulating T cells during cGvHD. Morita et al. reported 
the expression of CCR5 by a lymphoid infiltrate within the skin of patients with cGvHD, suggesting its role in 
the migration of T cells toward inflammatory sites (51). Interestingly, CD146/CCR5 double-positive CD4 T 
cells appeared to be enriched for a subset with a mixed polarization of Th1 and Th17, as attested by the coex-
pression of RORγt/T-bet and IFN-γ/IL-17. This subset has been shown to harbor a pathogenic role in several 
autoimmune diseases (52, 53). Indeed, Annunziato et al. previously showed that the Th1/Th17 subset showed 
increased cytotoxic capacity and lower susceptibility to the Treg suppressive activity (52). Comparably, Brüggen 
et al. observed a mixed Th1/Th17 signature in the skin of patients with lichenoid cGvHD (32).
To understand the role of  CD146-expressing T cells in the pathogenesis of  cGvHD, we utilized donor 
CD146-KO splenocytes in our multiorgan model of  cGvHD with BO manifestations (46). We observed a 
significant alleviation of  BO-cGvHD. Furthermore, we observed an increase in the pathogenic IFN-γ+IL-17+ 
subset within both CD146+ and CD146+CCR5+ fractions in the lung of  animals developing cGvHD that was 
alleviated when using CD146-KO splenocytes. In our model using splenocytes from CD146-KO mice, the 
remaining CD146+ or CD146+CCR5+ fractions, thus, appeared to differentiate from WT BM lymphoid pro-
genitors. However, the overall decrease in CD146+ and CD146+CCR5+ subsets may be consecutive to thymic 
injury from cGvHD and reduced production of  T cells.
Figure 5. Effect of RORγt inhibitor TMP778 on generation of Th1/Th17 cells and CD146+CCR5+ T cells among ICOS-differentiated 
Th17 cells. CD4+ T cells from healthy donors were activated with anti-CD3/anti-ICOS–coated beads under Th17-polarizing conditions in 
the presence of indicated concentrations of TMP778 and vehicle control DMSO. After 6 days, the expression of IL-17, IFN-γ, CD14, and 
CCR5 on T cells were measured by flow cytometry. (A) Representative plots of IL-17 and IFN-γ expression with mean ± SEM values for 
frequency of IFN-γ+IL-17+ T cells (n = 8). (B) Representative plots of CD146 and CCR5 expression with mean ± SEM values for frequency 
of CD146+CCR5+ T cells (n = 5). Comparisons in A–B were analyzed using a 1-sample t test comparing the mean linear rate of change, 
which was estimated for each value separately using least square estimation, to 0.
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We previously showed, in this model, the requirement of  alloantibody production from donor B cells 
differentiated during GC reaction, where TFH cells play a central role (46, 47). However, we didn’t observe 
any impact on TFH and GC B cell frequencies between CD146-KO and WT splenocyte conditions. This 
suggests that CD146-KO does not impair T-B cross talk and B cell differentiation into GC B cells and 
plasmablasts. Instead, CD146-KO appears to hamper Th17 cells that harbor profibrotic functions toward 
lung tissue, as we and other have previously shown (54, 55), thus explaining the improvement of  pulmonary 
function parameters. As we previously reported the role of  macrophages in the lung fibrosis, we analyzed 
macrophage infiltration using immunofluorescence and showed an increased infiltrate in murine cGvHD 
that was alleviated in mice receiving CD146-KO splenocytes. This underlines the central role of  Th17-po-
larized subsets, which harbor the capacity to secrete chemokines (CXCL8, CCL20, GM-CSF, IL-1β, and 
TNF-α), thus promoting a proinflammatory environment (48).
Because the CD146-expressing subset is Th17 polarized and appears as a key player of  cGvHD, we 
tested a small-molecule inhibitor of  the RORγt pathway to specifically target the Th17-derived subset. 
TMP778 is a pharmacological inhibitor that binds to RORγt to block downstream gene expression, such as 
IL-17A/F, IL-22, IL-23R,and CCR6, but also prevent a RORγt inhibitory effect on T-bet and GATA3 gene 
expression (40). TMP778 suppressed IL-17 and IFN-γ coproduction and diminished the CD146/CCR5 
double-positive subset not only from differentiated Th17 in vitro (ICOS-induced), but also in an alloreactive 
context (MLR). Importantly, TMP778 administration to mice receiving WT splenocytes alleviated lung 
cGvHD. Similarly, we observed BO alleviation when using anti–IL-17 blocking antibody, partly mimicking 
the downstream effect of  TMP778. In addition, RORγt program expression is dependent on the STAT3 
axis (56), as attested by reports on STAT3 deficiency (57) or STAT3 inhibitors (38, 58) inducing RORγt 
inhibition and Th17 deficiency. Thus, we also administered Cucurbitacin I, a potent STAT3 inhibitor, to 
evaluate upstream RORγt inhibition and observed BO alleviation at a similar level to TMP778 or CD146-
KO (data not shown).
In summary, our study provides data supporting the role of  CD1460-expressing CD4 T cells in the 
pathogenesis of  cGvHD, showing enhanced Th17 features also involved in other autoimmune diseases (44, 
59). This proposed cellular biomarker of  cGvHD would be required to be prospectively validated in order 
to justify clinical applications of  RORγt inhibitors showing promising preclinical results.
Methods
Supplemental Methods are available online with this article.
Mice. C57BL/6 (B6; H2b) mice were purchased from the National Cancer Institute. H2k mice were 
purchased from Jackson Laboratories. CD146-KO mice (on the H2b background) were provided for 
this study by Hong Wei Chu (National Jewish Health, Denver, Colorado, USA). Mice were housed in 
a specific pathogen–free facility.
BM transplant and therapeutic interventions in mice. H2k recipients were transplanted as previously described 
(31). Briefly, mice were given 2 doses of  cyclophosphamide (120 mg/Kg) i.p. and total body irradiation (TBI) 
Figure 6. IL-17 blocking anti-
body and RORγt inhibitor 
(TMP778) alleviates cGvHD. 
B10.BR mice were transplant-
ed with WT B6 BM only or 
with WT B6 T cells. As indi-
cated, cohorts of recipients 
receiving WT T cells received 
an IL-17 blocking antibody or 
a RORγt inhibitor (TMP778) 
beginning on day 28 after 
BMT. Mice were evaluated at 
day 56 for pulmonary func-
tion, n = 4–7 mice per group. 
Comparisons were analyzed 
using the Wilcoxon rank-sum 
test, with Bonferroni correc-
tion for multiple comparisons.
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(8.3 Gy). Mice were transplanted with 1 × 107 WT B6 BM cells supplemented with or without 0.6 × 105 to 0.8 
× 105 T cells from either WT or CD146-KO B6, where indicated. Where specified, cGvHD recipients were 
given anti–IL-17 (Centocor Biopharmaceutical) i.p. (250 μg/mice, twice a week from d28–d49). TMP778, 
prepared as described below, was given s.c. (600 μg/mice twice daily from d28–d42). Anti–IL-17 blocking 
antibody (5.1 mg/ml) or isotype (4.9 mg/ml) diluted in PBS were injected i.p. twice a week for 3 weeks.
Pulmonary function tests in mice. Anesthetized mice were weighed, unblinded animals were intubated, 
and lung function was assessed by whole body plethysmography using the Flexivent system (SCIREQ) and 
analyzed using the Flexivent software version 7.3.
Flow cytometry for murine in vitro and in vivo studies. Spleens, lymph nodes, lungs, and livers were harvest-
ed for IL-17 analysis on d28, d42, and d56, and single cell suspensions were made. The cells were stimu-
lated with Cell Stimulation Cocktail plus Protein Transport Inhibitors (eBioscience, 00-4975-93) for 5 hours 
at 37°C in complete-RPMI. Cells were stained with fixable viability dye eF780 or eF506 (eBioscience), anti-
CD4 (eBioscience, clone GK1.5), anti–IFN-γ (BD Biosciences, clone XMG1.2), anti–IL-17A (eBioscience, 
clone eBio17B7), anti–IL-21 (eBioscience, clone FFA21), anti-RORγt (eBioscience, clone B2D), anti-CCR5 
(eBioscience, clone HM-CCR5 [7A4]), anti-CD146 (BD Biosciences, clone ME-9F1), and anti-CD45.2 
(BD Biosciences, clone 104). All cells were fixed and permeabilized by the FOXP3 Fixation/Permeabiliza-
tion Concentrate and Diluent kit (eBioscience).
Frozen mouse tissue preparation. All organs harvested were embedded in OCT compound, snap fro-
zen in liquid nitrogen, and stored in –80°C. Lungs were inflated by infusing 1 ml of  OCT:PBS (3:1) 
intratracheally prior to harvest.
Histology and trichrome staining of  mouse tissues. Cryosections (6 μm) were fixed for 5 minutes in acetone 
and stained with H&E to determine pathology and with the Masson’s trichrome staining kit (Sigma-Al-
drich) for detection of  collagen deposition. Histopathology scores were assigned as previously described 
(46). Collagen deposition was quantified on trichrome-stained sections as a ratio of  area of  blue staining 
to area of  total staining using the Adobe Photoshop CS3 analysis tool. Collagen content was quantified 
by hydroxyproline assay (Sigma-Aldrich). Briefly, the left lobe of  each mouse was homogenized in 200 μl 
deionized (DI) water and then hydrolyzed in hydrochloric acid at 120ºC; 5–10 μl of  supernatant was trans-
ferred to a 96-well plate and evaporated to dryness. The amount of  hydroxyproline in the lung homogenate 
aliquot was measured by the hydroproline assay according to the protocol (60).
Patient characteristics. Laboratory studies were performed on frozen samples from 40 patients who 
underwent allogeneic HSCT at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital 
(Boston, Massachusetts, USA). Clinical characteristics of  these patients are summarized in Table 1. 
Chronic GvHD grade was established at the time of  sample collection using NIH guidelines (61) and 
summarized in Table 1. Biological samples were collected at the onset or flare of  cGvHD (70%) or in 
patients with stable active cGvHD disease (30%).
Flow cytometry for human studies. Thawed human PBMC were first stained using viability dye eF780 
(eBioscience). A panel of  surface markers was then used at 4°C for 20 minutes with fluorochrome-con-
jugated antibodies. The following reagents were used: CD3 (clone UCHT1), CD4 (clone SK3), CD25 
(clone M-A251), CD146 (clone P1H12), and CCR5 (clone 2D7) from BD Bioscience; CD45RA (clone 
IMU2711) from Beckman Coulter; and CD127 (clone eBioRDR5, eBioscience). To evaluate T cell polar-
ization, PBMC were stained using antibodies targeting intracellular antigens specific for Treg (FoxP3, clone 
PCH101, eBioscience), Th1 (T-bet, clone 4B10, BioLegend), and Th17 (RORγt, clone Q21-559, BD Bio-
sciences) with the FoxP3/Transcription Factor Staining kit (eBioscience). For cytokine flow cytometry, 
PBMC were stimulated with PMA (50 ng/ml) ionomycin (1 μM) (Sigma-Aldrich) in the presence of  Brefel-
din A (BD Biosciences) for 5 hours in RPMI1640, supplemented with 10% FBS, L-glutamine, and pencil-
line/streptamycine. Cells were then fixed and permeabilized with BD Cytofix/Cytoperm kit and stained 
with cytokine-specific antibodies: IFN-γ (clone B27) from BD Biosciences and IL-17 (clone eBio64Dec17) 
from eBioscience. Flow cytometry standards and quality controls were run regularly to ensure stability of  
the analytical instruments. A minimum of  150,000 events were recorded in the lymphocyte gate. Cells were 
analyzed using LSR Fortessa (BD Biosciences) and FlowJo v.10 software (Tree Star Inc.). For Treg suppres-
sion assay: PBMC from leukopacks (HDs) were enriched for CD4+ T cells (MACS-negative selection) and 
stained with CD4, CD25, CD127, and CD146. The following subsets were sorted using the FACSAria (BD 
Bioscience): Tcon (CD8–CD14–CD19–CD4+CD25–CD127+), Treg CD146+ (CD8–CD14–CD19–CD4+C-
D25hiCD127–CD146+), and Treg CD146– (CD8–CD14–CD19–CD4+CD25hiCD127–CD146–). Purity of  sort-
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ed subsets was > 95%. Tcon were stained with CFSE (1 μM). Treg and Tcon subsets were cocultured for 5 
days at different ratios upon stimulation with coated αCD3 (final concentration [Cf] = 5 μg/ml) and soluble 
αCD28 (Cf  = 3 μg/ml). At d5, cells were stained with a viability dye and read on Fortessa. For suppression, 
formula = (Tcon alone – [Tcon + Treg])/(Tcon alone) × 100.
RORγt and IL-17 targeting reagents. TMP778 powder, synthesized by GlaxoSmithKline and provided by 
Jianfei Yang (Tempero Pharmaceuticals a company of  GSK, Cambridge, Massachusetts, USA), was dis-
solved in DMSO at 808.76 mM and stored at –80°C as aliquots. Immediately before use, an aliquot of  
TMP778 stock solution was diluted in DMSO to 0.01 mM, 0.1 mM, and 1 mM and then further diluted 
by a factor of  1,000 in culture medium to final concentrations of  0.01 μM, 0.1 μM, and 1 μM, respectively. 
DMSO at 0.1% was used as vehicle control. For in vitro treatment, PBMCs were prepared from leukopacks 
of  HD (Central Indiana Blood Bank) by Ficoll-Paque density-grade centrifugation (GE Healthcare). Total 
CD4 T cells were positively isolated using human CD4 microbeads (Miltenyi Biotec) and activated for 6 days 
with anti-CD3/anti-ICOS antibody-coated Dynabeads M-450 Tosylactivated (Invitrogen) at a bead/cell ratio 
of  1:5 under the Th17-polarizing conditions: IL-1β (20 ng/ml), IL-6 (30 ng/ml), IL-23 (30 ng/ml), TGF-β 
(2 ng/ml), and neutralizing antibodies against IL-4 (5 μg/ml) and IFN-γ (2 μg/ml) (eBioscience). Exposure 
to differentiating cytokines (all from R&D Systems) and blocking antibodies was maintained throughout the 
culture period. For allogeneic MLR, irradiated (3,000 cGy) PBMCs from one donor were used as the stimula-
tor and mixed in a 1:1 ratio with PBMCs from another donor, used as the responder for 8–10 days. TMP778 
or DMSO vehicle control was added to the Th17 and MLR cultures on d0, replenished every 3 days, and 
maintained throughout the culture period. TMP778-treated Th17 or MLR cells were analyzed by flow cytom-
etry for cell-surface expression of  CD4, CD146, and CCR5. For intracellular cytokine staining of  IL-17 and 
IFN-γ, cells were stimulated with PMA (50 ng/ml; Sigma-Aldrich), ionomycin (1 μg/ml; Sigma-Aldrich), 
and brefeldin A (3 μg/ml) (eBioscience) for 5 hours. Intracellular cytokines were stained with the intracellular 
fixation and permeabilization buffer set (eBioscience). All staining antibodies were obtained from eBiosci-
ence. Stained cells were analyzed using an Attune Flow Cytometer (Invitrogen) and FlowJo software.
Statistics. Baseline clinical characteristics were compared between groups using either Fisher’s exact test 
or χ2 test for categorical variables or Wilcoxon rank-sum test for continuous variables. Phenotypic and func-
tional data were compared using Wilcoxon rank-sum test for unpaired group comparison and Wilcoxon 
signed-rank test for paired comparison. Prior to analysis, the normality assumption was examined. All tests 
were 2-sided at the significance level of  0.05. For Figure 6, each subplot involved 2 groupwise comparisons. 
To account for the type I error inflation due to multiple comparisons, we applied the Bonferroni correction. 
For Figure 5 and Supplemental Figure 6, we evaluated the mean linear rate of  change of  IL-17+IFN+ and 
CD146+CCR5+ as a function of  different concentrations of  a RORγt inhibitor, TMP778 (from 0–1 μM). To 
statistically evaluate this change, we performed a 1-sample t test comparing the mean linear rate of  change 
(e.g., slope), which was estimated for each value separately using least square estimation, to 0.
Statistical analyses and graphs for Figures 1–4 were performed using Prism software (GraphPad), and 
data are presented as mean ± SEM. Statistical analyses for Figures 5 and 6 and Supplemental Figure 6 were 
performed using STATA 14 for Windows.
Study approval. All studies were conducted in accordance with the GSK Policy on the Care, Welfare, and 
Treatment of  Laboratory Animals and were reviewed by the University of  Minnesota institutional animal 
care and use committee (IACUC 1504-32476A) and by Indiana University (IACUC 10488). All patients and 
HDs were enrolled in clinical research protocols approved by the Human Subjects Protection Committee of  
the Dana-Farber/Harvard Cancer Center (IRB 01-206). Written informed consent was obtained prior to sam-
ple collection, in accordance with the Declaration of  Helsinki. The human biological samples were sourced 
ethically, and their research use was in accord with the terms of  the informed consents.
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